IV infusion Adult weighing ≥80 kg 1,400 mg wkly for wk 1-4 (total of 4 doses), then every 2 wk at wk 5 onwards, weighing <80 kg 1,050 mg wkly for wk 1-4 (total of 4 doses), then every 2 wk at wk 5 onwards.
Risk of infusion-related reactions (IRRs); ILD or ILD-like adverse reactions (eg, pneumonitis); rash (including dermatitis acneiform), pruritus & dry skin; TEN; eye disorders, including keratitis. Administer premedications to reduce IRR risk. Interrupt treatment at 1st sign of IRRs & administer supportive medicinal products (eg, glucocorticoids, antihistamine, antipyretics, antiemetics) as clinically indicated. Monitor patients for symptoms indicative of ILD/pneumonitis; permanently discontinue in case of confirmed ILD. Patients should limit sun exposure during therapy & for 2 mth after Rybrevant therapy. Reduce dose, interrupt therapy or permanently discontinue based on severity of skin/nail reactions. Promptly refer patients to ophthalmologist in case of worsening eye symptoms; modify dose for Grade 3/4 eye disorders. Caution in patients w/ severe renal impairment & patients w/ moderate or severe hepatic impairment. Moderate influence on the ability to drive & use machines. Women of child-bearing potential should use effective contraception during & for 3 mth after cessation of treatment. Pregnancy & lactation.
Sign Out
